Advertisements



Novartis says top R&D executives no longer at Avexis unit after test data manipulation

Novartis said on Wednesday the two top research & development executives at its Avexis unit were no longer at the company after some data from early testing of Avexis's more than $2-million gene therapy Zolgensma was manipulated......»»

Category: topSource: reutersAug 14th, 2019

Novartis blames former AveXis executives for Zolgensma data manipulation

Novartis AG blamed former executives Brian and Allan Kaspar for the manipulation of data behind its $2.1 million gene therapy Zolgensma, saying they either personally manipulated the data or pressured subordinates into doing so......»»

Category: topSource: reutersSep 24th, 2019

Novartis replaces top scientists at Avexis after drug data manipulated

Novartis AG said on Wednesday it replaced the two top research and development executives at its Avexis unit after some data was manipulated from early testing of a gene therapy for infants that costs more than $2 million......»»

Category: topSource: reutersAug 14th, 2019

Novartis blames former Avexis executives for Zolgensma manipulation

Novartis AG .....»»

Category: topSource: reutersSep 24th, 2019

FDA: Novartis Hid Data Manipulation While Seeking Approval of $2.1 Million Drug

A Novartis AG unit that developed a breakthrough gene therapy knew about potential manipulation of animal testing data but failed to disclose it to regulators before the treatment was approved, the U.S. Food and Drug Administration said......»»

Category: topSource: moneycentralAug 6th, 2019

Novartis responds to FDA probe, details manipulation of data on gene therapy

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 25th, 2019

Novartis CEO promises to speed data integrity disclosures

Novartis Chief Executive Vas Narasimhan, facing an uproar over data manipulation involving $2.1 million gene therapy Zolgensma, pledged on Monday to tell regulators quickly if credible questions emerge in future over data integrity......»»

Category: topSource: reutersSep 9th, 2019

FDA zeroes in on Novartis delay in reporting data manipulation, WSJ reports

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 23rd, 2019

Novartis to respond to demand for data manipulation details, Reuters says

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 19th, 2019

Novartis to answer U.S. Senate demand for data manipulation details

Novartis plans to answer a U.S. senator who demanded details about data manipulation related to its gene therapy Zolgensma, amid scrutiny of the Swiss drugmaker's decision to delay informing regulators until after the treatment's approval......»»

Category: topSource: reutersAug 19th, 2019

Novartis executive sold shares before data manipulation made public,Reuters says

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 18th, 2019

Novartis executive sold shares before drug data manipulation made public

An unnamed Novartis executive sold 925,400 Swiss francs ($946,000) worth of shares less than three weeks before the U.S. Food and Drug Administration (FDA) announced data from tests of its gene therapy Zolgensma had been manipulated......»»

Category: topSource: reutersAug 18th, 2019

Novartis says Avexis" Chief Science Officer, head of R&D no longer at company

Nov.....»»

Category: topSource: reutersAug 14th, 2019

FDA Investigates Data Manipulation Issue With Newly Approved Novartis Drug Zolgensma

Novartis AG (NYSE: NVS)'s Zolgensma, the first gene therapy approved for pediatric patients with spinal muscular dystrophy Type 1, has caught the FDA's attention due to a disclo read more.....»»

Category: blogSource: benzingaAug 7th, 2019

Novartis falls while Biogen, Ionis rise after Zolgensma data manipulation issue

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 6th, 2019

Novartis stock falls after FDA says Zolgensma BLA had a "data manipulation issue"

Share.....»»

Category: topSource: marketwatchAug 6th, 2019

Novartis inks $8.7B AveXis buyout to build gene therapy unit - FierceBiotech

FierceBiotechNovartis inks $8.7B AveXis buyout to build gene therapy unitFierceBiotechNovartis has struck an $8.7 billion deal to buy AveXis. The move sees .....»»

Category: topSource: googlenewsApr 9th, 2018

Upstart Poaches GE Executives as It Chases Predix Customers

As General Electric Co. looks to shed parts of its software unit, smaller competitors see an opportunity to challenge the conglomerate in a business it had hoped to dominate—using data to improve the performance of industrial machines......»»

Category: smallbizSource: wsjAug 8th, 2018

Apple Signals "Disappointing Demand" As It Cancels Production Boost For iPhone XR

Just days after Apple unexpectedly announced it would no longer disclose quarterly unit sales data for its iPhones - a move which spooked marke.....»»

Category: blogSource: zerohedgeNov 5th, 2018

Novartis is tapping AWS to revamp manufacturing processes with AI and data analytics

This story was delivered to Busi.....»»

Category: topSource: businessinsiderDec 5th, 2019

Data Mining In The Health And Fitness Industry: What’s New?

In case you missed it, oil is no longer the world’s most valuable resource. According to The Economist, data is the new commodity fuelling growth... The post Data Mining In The Health And Fitness Industry: What’s New? appeared first on ValueWalk......»»

Category: blogSource: valuewalkDec 3rd, 2019